Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CSII intensive insulin therapy with metformin or dapagliflozin in newly diagnosed type 2 diabetes
ChiCTR1900025034Phase 4Recruiting
- Sponsor
- The Third Affiliated Hospital of Guangzhou Medical University
- Start
- Oct 2018
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of insulin lispro, metformin and dapagliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by The Third Affiliated Hospital of Guangzhou Medical University. Primary endpoints: fasting blood glucose, fasting insulin and 2 more. Started Oct 2018; status: recruiting.
02
Drugs
insulin lisprometformindapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR1900025034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025034.